TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02382757
Drug: insulin human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children will receive conventional treatment with human insulin according to standard medical practice.
Study: NCT01448044
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00499967
Drug: GS-9191 ointment
Normalized name: GS-9191
DrugBank: GS-9191 (DB15084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9191 ointment (0.01%, 0.03%, or 0.1%) or placebo applied topically to anogenital warts for one or three cycles, each cycle lasting 5 consecutive nights of ointment application followed by 9 nights off-ointment. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
Study: NCT00499967
Drug: GS-9191
Normalized name: GS-9191
DrugBank: GS-9191 (DB15084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9191 ointment (0.3% or 1.0%) or placebo applied topically to anogenital warts for one or three cycles; each cycle consists of dosing occuring over a 5-night period with ointment application on nights 1, 3 and 5 followed by a 9-day off-ointment period. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
Study: NCT03470259
Drug: IV adminstration of EMI-137
Normalized name: Oil of peppermint
DrugBank: EMI-137 (DB19174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of the fluorescent tracer EMI-137 approximately two hours before incision. Thereafter will be an observational period of an hour.
Study: NCT04518046
Drug: Sitravatinib
Normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
Study: NCT04518046
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
Study: NCT04518046
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
Study: NCT00647946
Drug: tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tenofovir DF 300mg once daily along with the other antiviral drugs
Study: NCT00647946
Drug: abacavir 300mg twice daily
Normalized name: abacavir 300 MG
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: abacavir 300mg twice daily along with the other antiviral drugs
Study: NCT00213200
Drug: morphine, amethocaine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01987362
Drug: RO6870810
Normalized name: BET INHIBITOR RO6870810
DrugBank: RO-6870810 (DB15151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive RO6870810 at different planned doses with a starting dose of 0.03 mg/kg to a maximum dose of 0.85 mg/kg SC on Days 1 to 14 in a 21-day treatment cycle or on Days 1 to 21 in a 28-day treatment cycle.
Study: NCT03054740
Drug: Gebauer Ethyl Chloride
Normalized name: Gebauer's Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be administered according to manufacturers recommendations which is to spray the aerosol can for 4-10 seconds from a distance of 3 to 9 inches. Do not spray longer than 10 seconds.
Study: NCT00343070
Drug: Oral administration of escitalopram during 8 weeks
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00312598
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01327846
Drug: Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02205034
Drug: oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration
Study: NCT03771105
Drug: phosphate
Normalized name: phosphate
DrugBank: Phosphate ion (DB14523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The target daily phosphate (Pi) intake is 3,500 mg/day (dietary intake plus our supplementation) for this study. Subjects will take a supplement of Pi (as KPhos Neutral 250 mg/tablet) to reach this target. Subjects will receive treatment for 30 days.
Study: NCT00046969
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03156855
Drug: Bismuth quadruple therapy
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
Study: NCT01843725
Drug: aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous 6mg/kg every 3 weeks
Study: NCT00719329
Drug: Chlorhexidine 4.0%
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution (4.0%, 7.1% CHX-D)
Study: NCT01635023
Drug: AZD6244 Dosing Period 3
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment A, B, or C depending on randomization assignment
Study: NCT02448329
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 80 mg/m2 given days 1, 8 and 15 of a 28 day cycle
Study: NCT01509001
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 750 to 2500 mg/day, two times a day during 4 months
Study: NCT01509001
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 to 8 mg/day , two times a dya, during 4 months.
Study: NCT02226978
Drug: Tipranavir
Normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02226978
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02226978
Drug: Valaciclovir
Normalized name: valaciclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01535027
Drug: teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: teriparatide 20 ug/day, sc.
Study: NCT01535027
Drug: teriparatide and raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: teriparatide 20 ug/day sc. raloxifene 60mg oral daily
Study: NCT01535027
Drug: teriparatide and alendronate
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: teriparatide 20 ug/day sc. alendronate 70mg oral weekly
Study: NCT00061633
Drug: Telavancin
Normalized name: Telavancin
DrugBank: Telavancin (DB06402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days
Study: NCT00061633
Drug: Vancomycin or antistaphylococcal penicillin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
Study: NCT02307045
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
Study: NCT02307045
Drug: nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy with transdermal patches and/or chewing gums
Study: NCT01509547
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants \>55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
Study: NCT03365947
Drug: JNJ-56136379
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT00042991
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00022737
Drug: asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IM
Study: NCT00022737
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00022737
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT and IV
Study: NCT00022737
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00022737
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00022737
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00022737
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00022737
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT00022737
Drug: pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IM
Study: NCT00022737
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01462006
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: randomized to drug or placebo, followed by washout, followed by crossover
Study: NCT00196703
Drug: memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004877
Drug: BMS-214662
Normalized name: BMS-214662
DrugBank: BMS-214662 (DB12234)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01584830
Drug: Regorafenib (BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)
Study: NCT03363139
Drug: Tirosin Kinase Inhibitors
Normalized name: VEGFR 2 Kinase inhibitor I
DrugBank: Rosin (DB11165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients that received Tyrosin Kinase inhibitors and progressed
Study: NCT00288002
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00288002
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00972322
Drug: MK-8245
Normalized name: MK-8245
DrugBank: MK-8245 (DB13024)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8245 50 mg twice daily for 28 days
Study: NCT01533753
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
Study: NCT01533753
Drug: Venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
Study: NCT00002720
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01372839
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
Study: NCT04454762
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral administration (40 mg daily, reduced dose 20 mg daily)
Study: NCT01225380
Drug: GS-9190
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9190 capsule, 20 mg BID, 16 or 24 weeks
Study: NCT01225380
Drug: GS-9256
Normalized name: GS-9256
DrugBank: GS-9256 (DB12876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9256 capsule, 150 mg BID, 16 or 24 weeks
Study: NCT04642469
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous administration of Durvalumab
Study: NCT01225380
Drug: GS-9256
Normalized name: GS-9256
DrugBank: GS-9256 (DB12876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9256 capsule, 150 mg BID, 24 weeks
Study: NCT01225380
Drug: GS-9256 placebo
Normalized name: GS-9256
DrugBank: GS-9256 (DB12876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching GS-9256 capsule BID, 24 weeks
Study: NCT00243906
Drug: Recombinant tissue plasminogen activator
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Plasminogen (DB16701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose IV rt-PA (0.6 mg/kg) followed by delivery of additional IA rt-PA (up to 22 mg).
Study: NCT01268904
Drug: Valproate
Normalized name: Valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures
Study: NCT04400110
Drug: Amoxicillin and Clavulanic Acid in Oral Dose Form
Normalized name: Product containing amoxicillin and clavulanic acid in oral dose form (medicinal product form)
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/kg three times daily administered orally
Study: NCT02859077
Drug: EGFR-TKI
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR-TKI (gefitinib)
Study: NCT02859077
Drug: Chemotherapy（pemetrexed/gemcitabine）
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy (pemetrexed/gemcitabine)
Study: NCT02859077
Drug: Chemotherapy（carboplatin）
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy（carboplatin）
Study: NCT04358432
Drug: AK102
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT04358432
Drug: Statins and/or Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lipid-lowering therapies
Study: NCT03309163
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patient-controlled intravenous analgesia with Tramadol
Study: NCT01042938
Drug: Curcumin C3 Complex
DrugBank: Cumin (DB10864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
Study: NCT03309163
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia with Hydromorphone
Study: NCT03309163
Drug: Ropivacaine (Epidural analgesia)
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia with Ropivacaine.
Study: NCT00725712
Drug: GSK1363089 (formerly XL880)
Normalized name: Lor-253(former code)
DrugBank: APTO-253 (DB17143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: c-MET tyrosine kinase inhibitor
Study: NCT03285607
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: -Standard of care
Study: NCT04420247
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 days of treatment with Chloroquine + Standard Care
Study: NCT04420247
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 days of treatment with Hydroxychloroquine + Standard Care
Study: NCT03838731
Drug: REGN1908-1909
Normalized name: Immunoglobulin G4 [227-proline], anti-(Felis catus allergen Fel d1) (human monoclonal REGN1908 γ4-chain), disulfide with human monoclonal REGN1908 κ-chain, dimer
DrugBank: Freneslerbart (DB19080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous (SC) dose of REGN1908 and REGN1909
Study: NCT01355874
Drug: Iferanserin
Normalized name: Iferanserin
DrugBank: Iferanserin (DB11686)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 14 days during double blind.
Study: NCT03774615
Drug: Ferric maltol 30 mg (Feraccru®)
Normalized name: ferric maltol 30 MG
DrugBank: Ferric maltol (DB15598)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
Study: NCT00269412
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01355874
Drug: Iferanserin + Placebo
DrugBank: Iferanserin (DB11686)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 7 days followed by placebo ointment BID for 7 days during the double blind.
Study: NCT04467918
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Already described
Study: NCT04465266
Drug: Tolperisone
Normalized name: tolperisone
DrugBank: Tolperisone (DB06264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT00004139
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004139
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004139
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00089960
Drug: AMG 706
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.
Study: NCT02412735
Drug: Rexlemestrocel-L
Normalized name: Rexlemestrocel-L
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rexlemestrocel-L injection
Study: NCT02412735
Drug: Rexlemestrocel-L + HA Mixture
Normalized name: brown mixture
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rexlemestrocel-L was combined in 1:1 by-volume ratio with HA solution and the resulting mixture was injected
Study: NCT02015507
Drug: ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02015507
Drug: VX-661
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02015507
Drug: ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00756041
Drug: TAK-128
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-128 100 mg tablet, orally, once daily for up to 1 year.
Study: NCT03405090
Drug: Combivent
Normalized name: Combivent
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer
Study: NCT03176264
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/kg every 2 weeks
Study: NCT01508949
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
Study: NCT02228525
Drug: selinexor (KPT-330)
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01644864
Drug: 0.375% ROPIVACAINE
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00400998
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive the following treatment regimen over one of two dosing periods within each of the three study phases:~- Intranasal FPANS (Fluticasone Propionate aqueous nasal spray) 200 mcg once daily for 8 to 14 days i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL (microlitres) i.e. 50 mcg fluticasone propionate.
Study: NCT01863147
Drug: Sitagliptin and acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.
Study: NCT02847429
Drug: Crenolanib
Normalized name: Crenolanib
DrugBank: Crenolanib (DB11832)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01046461
Drug: Ramosetron, Aprepitant, Dexamethasone
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1:~Aprepitant 125 mg PO, 1 hour before chemotherapy Ramosetron 0.6 mg IV, 30 min before chemotherapy Dexamethasone 12 mg PO, 30 min before chemotherapy~Day 2 - 3:~Aprepitant 80 mg PO. in the morning Dexamethasone 8 mg PO. in the morning~Day 4 Dexamethasone 8 mg PO. in the morning
Study: NCT01898377
Drug: Imatinib mesylate, Mycophenolate mofetil
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00224523
Drug: mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02926222
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib is formulated as tablets of 40mg for oral administration.